1Prystows EN, Bensen DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. A Statement for heahhcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart Association.Circulation, 1996, 93:1262-1277.
2Kopeeky SL, Gersh B J, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med, 1987, 317:669-674.
3Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the framingham study. N Engl J Med, 1982, 306:1018-1022.
5Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med, 2002, 347:1834-1840.
6Carlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF)study. JACC, 2003, 41:1690-1696.
7Gronefeld GC, Lilienthal J, Kuck KH, et al. Pharmacological- Intervention in atrial fibrillation. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J, 2003, 24, 1430-1436.
8Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
9Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationexecutive summary:a report of the American College of Cardiology/ American Heart Association task force on practice guidelines and the european society of cardiology committee for Practice guidelines(writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation).J Am Coll Cardiol, 2006, 48:854-906.
10Connollg S, Pogue J, Hart R, et al. Atrial fibrillation clopidogrel trial with irtesartan for prevention of vascular events(ACTIVE). Late breaking clinical report presented at the scientific sessions 2005 of the American Heart Association, Dallas, TX 2006.
二级参考文献15
1Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci[J]. Circulation, 2000, 101:1 409
2Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation[J]. Circulation, 2002, 105:1 077
3Yamane T, Shah DC, Jais P, et al. Electrogram polarity reversal as an additional indicator of breakthroughs from the left atrium to the pulmonary veins[J]. J Am Coll Cardiol, 2002, 39:1 337
4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy[J]. J Am Coll Cardiol, 2003, 41:1 633
5Wenger NK. Atrial fibrillation at elderly age: The importance of stroke prevention[J]. Am J Geriatr Cardiol, 1997, 6:35
6Roijer A, Eskilsson J, Olsson B. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion[J]. Eur Heart J, 2000, 21:837
7Spandorfer J. The management of anticoagulation before and after procedures[J]. Med Clin North Am, 2001, 85:1 109
8Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients[J]. PACE, 2003,26:511
9Gronefeld GC, Wegener F, Israel CW, et al. Thromboembolic risk of patients referred for radiofrequency catheter ablation of typical atrial flutter without prior appropriate anticoagulation therapy[J]. PACE, 2003,26:323
10Cauchemez B, Extramiana F, Cauchemez S, et al. High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium[J]. J Cardiovasc Electrophysiol, 2004,15:276
